Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M136,409Revenue $M39,498Net Margin (%)11.3Altman Z-Score2.7
Enterprise Value $M151,079EPS $1.6Operating Margin %17.5Piotroski F-Score6
P/E(ttm)13.1Beneish M-Score-2.6Pre-tax Margin (%)13.7Higher ROA y-yN
Price/Book3.010-y EBITDA Growth Rate %5.4Quick Ratio1.3Cash flow > EarningsY
Price/Sales3.55-y EBITDA Growth Rate %4.0Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow29.2y-y EBITDA Growth Rate %-8.2ROA % (ttm)5.2Higher Current Ratio y-yY
Dividend Yield %3.7PEG3.3ROE % (ttm)11.4Less Shares Outstanding y-yY
Payout Ratio %48.0Shares Outstanding M2,794ROIC % (ttm)12.3Gross Margin Increase y-yY

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKT Rowe Price Equity Income Fund 2015-12-31 Reduce-0.21%$49.47 - $55.53
($52.89)
$ 48.83-8%Reduce -14.63%5,610,000
MRKJames Barrow 2015-12-31 Add0.12%$49.47 - $55.53
($52.9)
$ 48.83-8%Add 5.86%26,655,176
MRKVanguard Health Care Fund 2015-12-31 Add0.08%$49.47 - $55.53
($52.9)
$ 48.83-8%Add 1.47%50,476,700
MRKKahn Brothers 2015-12-31 Add0.04%$49.47 - $55.53
($52.9)
$ 48.83-8%Add 0.47%1,010,927
MRKKen Fisher 2015-12-31 Add0.01%$49.47 - $55.53
($52.89)
$ 48.83-8%Add 0.89%6,822,070
MRKMario Gabelli 2015-12-31 Reduce$49.47 - $55.53
($52.9)
$ 48.83-8%Reduce -2.17%139,615
MRKVanguard Health Care Fund 2015-09-30 Add0.43%$48.42 - $59.71
($55.67)
$ 48.83-12%Add 8.73%49,743,388
MRKKahn Brothers 2015-09-30 Reduce-0.1%$48.42 - $59.71
($55.67)
$ 48.83-12%Reduce -1.02%1,006,208
MRKDavid Dreman 2015-09-30 Sold Out -0.05%$48.42 - $59.71
($55.67)
$ 48.83-12%Sold Out0
MRKJames Barrow 2015-09-30 Reduce-0.04%$48.42 - $59.71
($55.67)
$ 48.83-12%Reduce -1.80%25,179,076
MRKCharles Brandes 2015-09-30 Reduce-0.02%$48.42 - $59.71
($55.67)
$ 48.83-12%Reduce -0.90%2,791,984
MRKT Rowe Price Equity Income Fund 2015-09-30 Reduce-0.01%$48.42 - $59.71
($55.67)
$ 48.83-12%Reduce -0.82%6,571,200
MRKKen Fisher 2015-09-30 Reduce-0.01%$48.42 - $59.71
($55.67)
$ 48.83-12%Reduce -1.09%6,761,706
MRKMario Gabelli 2015-09-30 Reduce$48.42 - $59.71
($55.67)
$ 48.83-12%Reduce -3.92%142,715
MRKDodge & Cox 2015-09-30 Reduce$48.42 - $59.71
($55.67)
$ 48.83-12%Reduce -0.39%24,585,258
MRKNWQ Managers 2015-09-30 Reduce$48.42 - $59.71
($55.67)
$ 48.83-12%Reduce -5.36%69,835
MRKJoel Greenblatt 2015-09-30 Buy $48.42 - $59.71
($55.67)
$ 48.83-12%New holding5,844
MRKRuane Cunniff 2015-09-30 Add$48.42 - $59.71
($55.67)
$ 48.83-12%Add 4.39%4,994
MRKVanguard Health Care Fund 2015-06-30 Add0.65%$56.73 - $60.89
($58.76)
$ 48.83-17%Add 14.09%45,748,498
MRKCharles Brandes 2015-06-30 Add0.44%$56.73 - $60.89
($58.76)
$ 48.83-17%Add 26.81%2,817,473
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WEEKS WENDELL PDirector 2015-11-04Sell5,000$55.53-12.07view
AMBROSE ADELE DSr.V-P & Chief Comuns Officer 2015-10-29Sell37,313$55.08-11.35view
FRAZIER KENNETH CChairman, President & CEO 2015-10-29Sell18,666$54.69-10.71view
WENDELL PETER CDirector 2015-10-28Sell5,000$54.85-10.98view
Golestani ClarkEVP & Chief Info Officer 2015-07-31Sell31,831$59.09-17.36view
Schechter Adam HEVP & Pres-Global Human Health 2015-05-11Sell10,634$60.44-19.21view
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy 2015-05-08Sell38,368$60.99-19.94view
Kuhlik Bruce NExe V-P & Gen Counsel 2015-05-04Sell56,064$60.2-18.89view
Holston Michael JEVP, Legal 2015-04-29Sell95,624$59.84-18.4view
Kuhlik Bruce NExe V-P & Gen Counsel 2015-04-29Sell156,902$59.82-18.37view

Press Releases about MRK :

Quarterly/Annual Reports about MRK:

    News about MRK:

    Articles On GuruFocus.com
    Richard Snow Makes Huge Increases in Big-Name Stocks Jan 08 2016 
    5 Top Stocks of the Outperforming Vanguard Health Care Fund Dec 28 2015 
    5 Guru Picks in Volatile Biotech Industry Dec 23 2015 
    Kahn Brothers' Largest Sales During 3rd Quarter Dec 22 2015 
    Vanguard Raises Stakes in Biogen, Mylan, Merck Nov 15 2015 
    Richard Snow Invests in Familiar Names in 3rd Quarter Nov 13 2015 
    Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? Nov 12 2015 
    Pfizer to Create a New Pharmaceutical Colossus Nov 05 2015 
    Vanguard Health Care Fund Buys Biogen and Mylan, Cuts Pfizer Nov 02 2015 
    Charles Brandes' Most Weighted Trades in Q2 2015 Sep 30 2015 

    More From Other Websites
    Why Novo Nordisk Fell after Its 4Q15 Earnings Release Feb 08 2016
    Major Developments for Eli Lilly and Co. in 4Q15 Feb 08 2016
    The 'Dogs Of The Dow' Are Outperforming The Index, Here's How Too Trade Them Feb 08 2016
    Top of The List: Largest Biotech/Pharma Companies and Largest CROs Feb 08 2016
    4 Big Dividend Pharmaceutical Stocks to Buy That Are Very Cheap Now Feb 08 2016
    Where is Ronald Reagan When You Need Him? Feb 08 2016
    These 5 Rocket Stocks Could Blast Higher in February Feb 08 2016
    How Analysts View Pfizer and Merck After Earnings Feb 07 2016
    ImmunoGen/Merck Collaborate for Ovarian Cancer Study Feb 05 2016
    Merck & Co., Inc. Earnings Analysis: 2015 By the Numbers Feb 05 2016
    FDA staff supports Celltrion's biosimilar Remicade Feb 05 2016
    String of Q4 Earnings Beat Fails to Revive Pharma ETFs Feb 05 2016
    FDA reviewers support Celltrion's biosimilar Remicade Feb 05 2016
    It’s Time to Buy This Biotech Gem Feb 04 2016
    Here's why ImmunoGen's CEO is psyched for combo tests with Keytruda Feb 04 2016
    FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination... Feb 04 2016
    Emerging Situations, Growth Study - Analyst Notes on Apple, Merck & Co, Wal Mart Stores and Home... Feb 04 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK